| ID Source | ID |
|---|---|
| PubMed CID | 135473061 |
| CHEMBL ID | 3277911 |
| MeSH ID | M0090731 |
| Synonym |
|---|
| isonicotinaldehyde, 3-hydroxy-5-(hydroxymethyl)-2-methyl-, oxime |
| oxime du pyridoxal [french] |
| brn 0153114 |
| pyridoxaloxime |
| pyridoxal, oxime |
| 4-[(e)-hydroxyiminomethyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol |
| 708-08-7 |
| SR-01000640129-1 |
| NCGC00175872-01 |
| HMS1530L01 |
| BRD-K38056763-001-01-8 |
| AKOS006243391 |
| oxime du pyridoxal |
| pyridoxal oxime |
| 5-21-13-00052 (beilstein handbook reference) |
| CCG-50781 |
| CHEMBL3277911 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1151054 | Growth inhibition of mouse TA3 cells | 1976 | Journal of medicinal chemistry, Aug, Volume: 19, Issue:8 | Synthesis and biological properties of 4-amino- and 4-bromo-4-norpyridoxol. New approaches for the modification of the 4 position of vitamin B6. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||